RU2639537C2 - Фосфоспецифичные антитела, распознающие тау - Google Patents
Фосфоспецифичные антитела, распознающие тау Download PDFInfo
- Publication number
- RU2639537C2 RU2639537C2 RU2014118456A RU2014118456A RU2639537C2 RU 2639537 C2 RU2639537 C2 RU 2639537C2 RU 2014118456 A RU2014118456 A RU 2014118456A RU 2014118456 A RU2014118456 A RU 2014118456A RU 2639537 C2 RU2639537 C2 RU 2639537C2
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- seq
- tau
- amino acid
- acid sequence
- Prior art date
Links
- -1 Phospho Chemical class 0.000 title claims description 25
- 102000013498 tau Proteins Human genes 0.000 claims abstract description 370
- 108010026424 tau Proteins Proteins 0.000 claims abstract description 370
- 239000012634 fragment Substances 0.000 claims abstract description 173
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 112
- 238000000034 method Methods 0.000 claims abstract description 96
- 210000004556 brain Anatomy 0.000 claims abstract description 94
- 201000010099 disease Diseases 0.000 claims abstract description 72
- 208000035475 disorder Diseases 0.000 claims abstract description 40
- 238000001514 detection method Methods 0.000 claims abstract description 35
- 241001465754 Metazoa Species 0.000 claims abstract description 30
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 29
- 239000002157 polynucleotide Substances 0.000 claims abstract description 29
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 25
- 230000004044 response Effects 0.000 claims abstract description 14
- 208000007660 Residual Neoplasm Diseases 0.000 claims abstract description 6
- 230000028993 immune response Effects 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 239000013598 vector Substances 0.000 claims abstract description 6
- 238000012544 monitoring process Methods 0.000 claims abstract description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 203
- 108090000623 proteins and genes Proteins 0.000 claims description 95
- 102000004169 proteins and genes Human genes 0.000 claims description 91
- 241000282414 Homo sapiens Species 0.000 claims description 90
- 230000001900 immune effect Effects 0.000 claims description 68
- 210000004027 cell Anatomy 0.000 claims description 62
- 210000004408 hybridoma Anatomy 0.000 claims description 59
- 208000024827 Alzheimer disease Diseases 0.000 claims description 53
- 241000124008 Mammalia Species 0.000 claims description 53
- 239000002773 nucleotide Substances 0.000 claims description 35
- 125000003729 nucleotide group Chemical group 0.000 claims description 35
- 230000015572 biosynthetic process Effects 0.000 claims description 31
- 230000001575 pathological effect Effects 0.000 claims description 30
- 150000007523 nucleic acids Chemical class 0.000 claims description 25
- 210000001320 hippocampus Anatomy 0.000 claims description 23
- 102000039446 nucleic acids Human genes 0.000 claims description 23
- 108020004707 nucleic acids Proteins 0.000 claims description 23
- 238000010494 dissociation reaction Methods 0.000 claims description 18
- 230000005593 dissociations Effects 0.000 claims description 18
- 206010012289 Dementia Diseases 0.000 claims description 17
- 208000034799 Tauopathies Diseases 0.000 claims description 16
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 15
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 15
- 210000003710 cerebral cortex Anatomy 0.000 claims description 13
- 230000014509 gene expression Effects 0.000 claims description 12
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 10
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 9
- 206010034010 Parkinsonism Diseases 0.000 claims description 9
- 238000009007 Diagnostic Kit Methods 0.000 claims description 8
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 7
- 201000010374 Down Syndrome Diseases 0.000 claims description 5
- 206010059245 Angiopathy Diseases 0.000 claims description 4
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 4
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 4
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 4
- 201000002481 Myositis Diseases 0.000 claims description 4
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 4
- 108091000054 Prion Proteins 0.000 claims description 4
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims description 4
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 4
- 230000002308 calcification Effects 0.000 claims description 4
- 230000007850 degeneration Effects 0.000 claims description 4
- 210000002161 motor neuron Anatomy 0.000 claims description 4
- 230000009529 traumatic brain injury Effects 0.000 claims description 4
- 206010018341 Gliosis Diseases 0.000 claims description 3
- 210000000349 chromosome Anatomy 0.000 claims description 3
- 230000002068 genetic effect Effects 0.000 claims description 3
- 230000007387 gliosis Effects 0.000 claims description 3
- 210000003000 inclusion body Anatomy 0.000 claims description 3
- 206010003694 Atrophy Diseases 0.000 claims description 2
- 102000029797 Prion Human genes 0.000 claims description 2
- 230000037444 atrophy Effects 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 208000017004 dementia pugilistica Diseases 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 13
- 239000003814 drug Substances 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 9
- 238000003745 diagnosis Methods 0.000 abstract description 5
- 102100027831 14-3-3 protein theta Human genes 0.000 abstract description 4
- 230000006698 induction Effects 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000027455 binding Effects 0.000 description 341
- 108090000765 processed proteins & peptides Proteins 0.000 description 286
- 235000018102 proteins Nutrition 0.000 description 87
- 102000004196 processed proteins & peptides Human genes 0.000 description 62
- 239000000203 mixture Substances 0.000 description 48
- 239000000523 sample Substances 0.000 description 43
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 40
- 229940024606 amino acid Drugs 0.000 description 40
- 235000001014 amino acid Nutrition 0.000 description 40
- 150000001413 amino acids Chemical class 0.000 description 38
- 230000007170 pathology Effects 0.000 description 34
- 239000008187 granular material Substances 0.000 description 32
- 239000002953 phosphate buffered saline Substances 0.000 description 32
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 31
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 30
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 30
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 29
- 208000015122 neurodegenerative disease Diseases 0.000 description 29
- 238000001727 in vivo Methods 0.000 description 24
- 101000651298 Homo sapiens TRAF-interacting protein with FHA domain-containing protein A Proteins 0.000 description 23
- 102100027651 TRAF-interacting protein with FHA domain-containing protein A Human genes 0.000 description 23
- 238000012815 AlphaLISA Methods 0.000 description 22
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 description 22
- 102000057063 human MAPT Human genes 0.000 description 22
- 238000003556 assay Methods 0.000 description 20
- 238000001262 western blot Methods 0.000 description 20
- 239000000427 antigen Substances 0.000 description 19
- 108091007433 antigens Proteins 0.000 description 19
- 102000036639 antigens Human genes 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 238000005406 washing Methods 0.000 description 19
- 239000000872 buffer Substances 0.000 description 17
- 230000004770 neurodegeneration Effects 0.000 description 17
- 230000000890 antigenic effect Effects 0.000 description 15
- 230000009261 transgenic effect Effects 0.000 description 15
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 14
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 229960005486 vaccine Drugs 0.000 description 13
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 12
- 229920001213 Polysorbate 20 Polymers 0.000 description 12
- 210000004727 amygdala Anatomy 0.000 description 12
- 230000008499 blood brain barrier function Effects 0.000 description 12
- 210000001218 blood-brain barrier Anatomy 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 12
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 12
- 238000010186 staining Methods 0.000 description 12
- 101000854943 Enterobacteria phage T4 Valyl-tRNA ligase modifier Proteins 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 108060003951 Immunoglobulin Proteins 0.000 description 10
- 102000018358 immunoglobulin Human genes 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 108010090804 Streptavidin Proteins 0.000 description 9
- 230000002163 immunogen Effects 0.000 description 9
- 230000026731 phosphorylation Effects 0.000 description 9
- 238000006366 phosphorylation reaction Methods 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000011065 in-situ storage Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 7
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 102000029749 Microtubule Human genes 0.000 description 7
- 108091022875 Microtubule Proteins 0.000 description 7
- 108010001441 Phosphopeptides Proteins 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 239000012131 assay buffer Substances 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 210000004688 microtubule Anatomy 0.000 description 7
- 239000000178 monomer Substances 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 6
- 102000001708 Protein Isoforms Human genes 0.000 description 6
- 108010029485 Protein Isoforms Proteins 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 239000012491 analyte Substances 0.000 description 6
- 229960002685 biotin Drugs 0.000 description 6
- 235000020958 biotin Nutrition 0.000 description 6
- 239000011616 biotin Substances 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 230000003920 cognitive function Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000009169 immunotherapy Methods 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000011830 transgenic mouse model Methods 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 5
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 5
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 5
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000007413 biotinylation Methods 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 230000001771 impaired effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000004179 neuropil Anatomy 0.000 description 5
- 229920000747 poly(lactic acid) Polymers 0.000 description 5
- 230000000750 progressive effect Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 241000208199 Buxus sempervirens Species 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 108010067902 Peptide Library Proteins 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 102000007562 Serum Albumin Human genes 0.000 description 4
- 108010071390 Serum Albumin Proteins 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 101710120037 Toxin CcdB Proteins 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000009260 cross reactivity Effects 0.000 description 4
- 208000037765 diseases and disorders Diseases 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000002055 immunohistochemical effect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000002981 neuropathic effect Effects 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000002123 temporal effect Effects 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010029350 Neurotoxicity Diseases 0.000 description 3
- 208000037658 Parkinson-dementia complex of Guam Diseases 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010044221 Toxic encephalopathy Diseases 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 208000013968 amyotrophic lateral sclerosis-parkinsonism-dementia complex Diseases 0.000 description 3
- 208000014450 amyotrophic lateral sclerosis-parkinsonism/dementia complex 1 Diseases 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 230000006287 biotinylation Effects 0.000 description 3
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 3
- 239000012152 bradford reagent Substances 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 239000000544 cholinesterase inhibitor Substances 0.000 description 3
- 230000001149 cognitive effect Effects 0.000 description 3
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000000971 hippocampal effect Effects 0.000 description 3
- 238000003165 hybrid screening Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000002197 limbic effect Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000000626 neurodegenerative effect Effects 0.000 description 3
- 231100000228 neurotoxicity Toxicity 0.000 description 3
- 230000007135 neurotoxicity Effects 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- LZXHHNKULPHARO-UHFFFAOYSA-M (3,4-dichlorophenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].C1=C(Cl)C(Cl)=CC=C1C[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 LZXHHNKULPHARO-UHFFFAOYSA-M 0.000 description 2
- NQRKYASMKDDGHT-UHFFFAOYSA-N (aminooxy)acetic acid Chemical compound NOCC(O)=O NQRKYASMKDDGHT-UHFFFAOYSA-N 0.000 description 2
- SNKZJIOFVMKAOJ-UHFFFAOYSA-N 3-Amino-1-propanesulfonic acid Natural products NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 description 2
- 102100034452 Alternative prion protein Human genes 0.000 description 2
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 208000011359 Chromosome disease Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229910018828 PO3H2 Inorganic materials 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 229960004372 aripiprazole Drugs 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 239000003693 atypical antipsychotic agent Substances 0.000 description 2
- 229940127236 atypical antipsychotics Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229940088623 biologically active substance Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000013377 clone selection method Methods 0.000 description 2
- 229960004170 clozapine Drugs 0.000 description 2
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 208000035474 group of disease Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000011327 histological measurement Methods 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 210000004754 hybrid cell Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 201000010901 lateral sclerosis Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 208000005264 motor neuron disease Diseases 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- QNDVLZJODHBUFM-WFXQOWMNSA-N okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 description 2
- VEFJHAYOIAAXEU-UHFFFAOYSA-N okadaic acid Natural products CC(CC(O)C1OC2CCC3(CCC(O3)C=CC(C)C4CC(=CC5(OC(CC(C)(O)C(=O)O)CCC5O)O4)C)OC2C(O)C1C)C6OC7(CCCCO7)CCC6C VEFJHAYOIAAXEU-UHFFFAOYSA-N 0.000 description 2
- 229960005017 olanzapine Drugs 0.000 description 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 229940023041 peptide vaccine Drugs 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000008024 pharmaceutical diluent Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000003504 photosensitizing agent Substances 0.000 description 2
- 238000000053 physical method Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960001534 risperidone Drugs 0.000 description 2
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 239000012536 storage buffer Substances 0.000 description 2
- 230000002739 subcortical effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 229960000607 ziprasidone Drugs 0.000 description 2
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- KYZWKYWGQFCRGN-OASOTCBPSA-N (2s)-2-aminopentanedioic acid;(2r)-2-(methylamino)butanedioic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O.OC(=O)[C@@H](N)CCC(O)=O KYZWKYWGQFCRGN-OASOTCBPSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- CMUGHZFPFWNUQT-HUBLWGQQSA-N 6-[5-(2-oxo-hexahydro-thieno[3,4-d]imidazol-4-yl)-pentanoylamino]-hexanoic acid Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)O)SC[C@@H]21 CMUGHZFPFWNUQT-HUBLWGQQSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 102100026882 Alpha-synuclein Human genes 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102000014303 Amyloid beta-Protein Precursor Human genes 0.000 description 1
- 108010079054 Amyloid beta-Protein Precursor Proteins 0.000 description 1
- 206010002023 Amyloidoses Diseases 0.000 description 1
- 208000007415 Anhedonia Diseases 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 230000007082 Aβ accumulation Effects 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 101150053721 Cdk5 gene Proteins 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- 102000001267 GSK3 Human genes 0.000 description 1
- 108060006662 GSK3 Proteins 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 229910020700 Na3VO4 Inorganic materials 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- GKKYVDHUZBHXGE-UHFFFAOYSA-N O.O.O.O.O.O.[Na].[Na] Chemical compound O.O.O.O.O.O.[Na].[Na] GKKYVDHUZBHXGE-UHFFFAOYSA-N 0.000 description 1
- 101001028244 Onchocerca volvulus Fatty-acid and retinol-binding protein 1 Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 238000012879 PET imaging Methods 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241000232971 Passer domesticus Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 102000015499 Presenilins Human genes 0.000 description 1
- 108010050254 Presenilins Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 206010048327 Supranuclear palsy Diseases 0.000 description 1
- 102100033504 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000007238 Transferrin Receptors Human genes 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000007791 alzheimer disease like pathology Effects 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
- HFNQLYDPNAZRCH-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O.OC(O)=O HFNQLYDPNAZRCH-UHFFFAOYSA-N 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000012303 cytoplasmic staining Methods 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 210000001947 dentate gyrus Anatomy 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229940084910 gliadel Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000003825 glutamate receptor antagonist Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 1
- 229960004135 idebenone Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 210000002511 neuropil thread Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 1
- 229960004633 pirenzepine Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- MGNVWUDMMXZUDI-UHFFFAOYSA-N propane-1,3-disulfonic acid Chemical compound OS(=O)(=O)CCCS(O)(=O)=O MGNVWUDMMXZUDI-UHFFFAOYSA-N 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000003976 synaptic dysfunction Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000007633 synaptic toxicity Effects 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000011816 wild-type C57Bl6 mouse Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2011/067604 | 2011-10-07 | ||
| PCT/EP2011/067604 WO2012045882A2 (en) | 2010-10-07 | 2011-10-07 | Pharmaceutical composition |
| EP12163319 | 2012-04-05 | ||
| EP12163319.2 | 2012-04-05 | ||
| PCT/EP2012/069783 WO2013050567A1 (en) | 2011-10-07 | 2012-10-05 | Phosphospecific antibodies recognising tau |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2014118456A RU2014118456A (ru) | 2015-11-20 |
| RU2639537C2 true RU2639537C2 (ru) | 2017-12-21 |
Family
ID=48043196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014118456A RU2639537C2 (ru) | 2011-10-07 | 2012-10-05 | Фосфоспецифичные антитела, распознающие тау |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9540434B2 (zh) |
| EP (2) | EP3135689B1 (zh) |
| JP (1) | JP6358953B2 (zh) |
| KR (1) | KR101981351B1 (zh) |
| CN (2) | CN108034005B (zh) |
| AR (1) | AR092779A1 (zh) |
| BR (2) | BR122021017560B1 (zh) |
| CA (1) | CA2850686C (zh) |
| ES (1) | ES2600915T3 (zh) |
| HK (1) | HK1200469A1 (zh) |
| MX (1) | MX354662B (zh) |
| RU (1) | RU2639537C2 (zh) |
| WO (1) | WO2013050567A1 (zh) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR092779A1 (es) | 2011-10-07 | 2015-05-06 | Ac Immune Sa | Composicon farmaceutica que comprende anticuerpos que se unen a conformeros de proteinas tau |
| CA2869438C (en) | 2012-04-05 | 2021-08-17 | Ac Immune S.A. | Humanized tau antibody |
| RU2668159C2 (ru) | 2012-07-03 | 2018-09-26 | Вашингтон Юниверсити | Антитела против тау |
| BR112015003326A2 (pt) | 2012-08-16 | 2017-07-04 | Ipierian Inc | métodos de tratamento de uma tauopatia |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| JP6674888B2 (ja) | 2013-03-13 | 2020-04-01 | プロセナ バイオサイエンシーズ リミテッド | タウ免疫療法 |
| JP6568514B2 (ja) | 2013-03-15 | 2019-08-28 | エーシー イミューン エス．エー． | 抗タウ抗体及び使用方法 |
| GB201319656D0 (en) * | 2013-11-07 | 2013-12-25 | Univ Leuven Kath | A yeast model for synergistic toxicity |
| US10400018B2 (en) | 2014-02-14 | 2019-09-03 | Ipierian, Inc. | Tau peptides, anti-tau antibodies, and methods of use thereof |
| US10400034B2 (en) * | 2014-06-26 | 2019-09-03 | Janssen Vaccines & Prevention, B.V. | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| ZA201608812B (en) * | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| TWI664190B (zh) | 2014-06-27 | 2019-07-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗－ｔａｕ抗體 |
| WO2016007414A1 (en) * | 2014-07-08 | 2016-01-14 | New York University | Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy |
| DE102014013571A1 (de) * | 2014-09-18 | 2016-03-24 | Aj Roboscreen Gmbh | Monoklonaler Antikörper gegen humanes TAU-Protein |
| EP3200832B1 (en) | 2014-09-30 | 2020-07-29 | Washington University | Tau kinetic measurements |
| JO3576B1 (ar) | 2015-02-26 | 2020-07-05 | Lilly Co Eli | أجسام مضادة لـ tau واستخداماتها |
| JP6793134B2 (ja) | 2015-06-05 | 2020-12-02 | ジェネンテック， インコーポレイテッド | 抗ｔａｕ抗体及び使用方法 |
| JO3711B1 (ar) * | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| US10358503B2 (en) * | 2015-08-13 | 2019-07-23 | New York University | Antibody-based molecules selective for the {P}Ser404 epitope of Tau and their uses in the diagnosis and treatment of tauopathy |
| KR102533675B1 (ko) | 2016-05-02 | 2023-05-22 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
| FI3452507T3 (fi) | 2016-05-02 | 2022-12-15 | Tau-immuunihoito | |
| EA201892417A1 (ru) | 2016-05-02 | 2019-05-31 | Протена Биосайенсис Лимитед | Антитела, распознающие тау |
| GEP20217222B (en) | 2016-07-12 | 2021-02-10 | Lundbeck A/S H | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
| US10988529B2 (en) | 2016-08-09 | 2021-04-27 | Eli Lilly And Company | Combination therapy |
| AR110321A1 (es) * | 2016-12-07 | 2019-03-20 | Genentech Inc | Anticuerpos antitau y métodos de uso |
| JP2020511937A (ja) | 2016-12-07 | 2020-04-23 | ジェネンテック， インコーポレイテッド | 抗ｔａｕ抗体及び使用方法 |
| MA47205A (fr) * | 2017-01-04 | 2019-11-13 | H Lundbeck As | Anticorps spécifiques de la protéine tau hyperphosphorylée pour traiter des maladies oculaires |
| WO2018152359A1 (en) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
| EA039569B1 (ru) * | 2017-03-14 | 2022-02-11 | Х. Лундбекк А/С | Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения |
| CN110881274A (zh) | 2017-05-02 | 2020-03-13 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
| TW201946654A (zh) * | 2018-03-05 | 2019-12-16 | 比利時商健生藥品公司 | 抗ＰＨＦ－Ｔａｕ抗體及其用途 |
| CA3090356A1 (en) * | 2018-03-11 | 2019-09-19 | Koorosh Shahpasand | Conformation-independent antibodies against neurotoxic tau proteins |
| US11085935B2 (en) | 2018-05-03 | 2021-08-10 | Washington University | Methods of treating based on site-specific tau phosphorylation |
| MX2020011458A (es) * | 2018-05-03 | 2020-12-07 | Washington University St Louis | Metodos de diagnostico y tratamiento basados en fosforilacion de tau especifica del sitio. |
| WO2020028141A1 (en) | 2018-07-31 | 2020-02-06 | Eli Lilly And Company | Combination therapy |
| US12016885B2 (en) | 2018-11-06 | 2024-06-25 | Alsatech, Inc. | Method of solubilizing TDP-43 protein aggregates in amyotrophic lateral sclerosis using a microvascular endothelial cell expressing an anti-TDP-43 Fab |
| BR112021016947A2 (pt) | 2019-03-03 | 2021-11-03 | Prothena Biosciences Ltd | Anticorpos que reconhecem tau |
| EP3948295A1 (en) * | 2019-03-28 | 2022-02-09 | H. Lundbeck A/S | Use of a ps396 assay to diagnose tauophaties |
| CA3148740A1 (en) * | 2019-08-06 | 2021-02-11 | Aprinoia Therapeutics Limited | Antibodies that bind to pathological tau species and uses thereof |
| CN111690061B (zh) * | 2020-06-28 | 2022-08-23 | 中国人民解放军东部战区疾病预防控制中心 | 人源化抗鼠疫耶尔森菌抗原f1的抗体及应用 |
| EP4252243A2 (en) | 2020-11-30 | 2023-10-04 | Enigma Biointelligence, Inc. | Non-invasive assessment of alzheimer's disease |
| MX2023007181A (es) * | 2020-12-16 | 2023-08-30 | Voyager Therapeutics Inc | Compuestos de union a tau. |
| CN112694532B (zh) * | 2021-01-12 | 2023-04-18 | 倍而达药业（苏州）有限公司 | 抗Siglec-15的抗体或其抗原结合片段及应用 |
| CN113533746B (zh) * | 2021-07-22 | 2022-05-10 | 深圳市天大生物医疗器械有限公司 | 一种P-Tau蛋白化学发光检测试剂盒及其制备方法 |
| CN114002435A (zh) * | 2021-10-13 | 2022-02-01 | 华中科技大学 | 三种用于检测人磷酸化Tau蛋白的试剂盒及其制备方法 |
| WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CN117003863A (zh) * | 2022-04-28 | 2023-11-07 | 厦门大学 | 针对p-tau 217的抗体及其用途 |
| CN114778856B (zh) * | 2022-05-30 | 2023-03-17 | 苏州宇测生物科技有限公司 | 磷酸化tau蛋白检测试剂盒 |
| CN117866087B (zh) * | 2024-03-11 | 2024-05-17 | 江西赛基生物技术有限公司 | 一种抗pTau181单克隆抗体及其应用 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998022120A1 (en) * | 1996-11-19 | 1998-05-28 | The Wistar Institute Of Anatomy & Biology | Diagnostic and therapeutic reagents for alzheimer's disease |
| RU2299889C2 (ru) * | 2001-02-02 | 2007-05-27 | Аксон Нойрошинс Форшунгс-Унд Энтвиклунгс Гмбх | Конформационно аномальные формы белков тау и специфические антитела к ним |
| US20080050383A1 (en) * | 2006-03-29 | 2008-02-28 | New York University | Immunotherapy for clearing pathological tau conformers |
| US20090162336A1 (en) * | 1991-12-06 | 2009-06-25 | Max-Planck-Gesellschaft Zur Forderungder Wissenschaften, E.V. | Novel Tools for the Diagnosis and Treatment of Alzheimer's Disease |
| WO2010106127A2 (en) * | 2009-03-18 | 2010-09-23 | Ac Immune S.A. | Method for therapeutic use |
| WO2010115843A2 (en) * | 2009-04-03 | 2010-10-14 | Ac Immune S.A. | Pharmaceutical composition |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| ATE206755T1 (de) * | 1991-08-09 | 2001-10-15 | Massachusetts Inst Technology | Verwendungen einer proteinkinase von ton und neurofilament pk40 |
| CA2141216A1 (en) | 1992-07-27 | 1994-02-03 | Michael J. Micklus | Targeting of liposomes to the blood-brain barrier |
| JPH10507643A (ja) | 1994-10-21 | 1998-07-28 | イノジェネティックス・ナムローゼ・フェンノートシャップ | Ｃ型肝炎ウイルス遺伝子型の新規配列、ならびにそれらの予防薬、治療薬および診断薬としての使用 |
| US5756662A (en) | 1995-03-14 | 1998-05-26 | Corixa Corporation | Compounds and methods for the detection of T. cruzi infection |
| US20020086009A1 (en) | 1996-03-13 | 2002-07-04 | Koichi Ishiguro | Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same |
| MXPA03000316A (es) | 2000-07-11 | 2004-04-05 | Molecular Geriatrics Corp | Reactivos y metodos para la identificacion de agentes de enlace. |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| AU2001286930A1 (en) | 2000-08-30 | 2002-03-13 | The Board Of Trustees Of The Leland Stanford Junior University | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| US20030083299A1 (en) | 2000-11-04 | 2003-05-01 | Ferguson Ian A. | Non-invasive delivery of polypeptides through the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| DE60234057D1 (de) | 2001-07-25 | 2009-11-26 | Raptor Pharmaceutical Inc | Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| KR101111477B1 (ko) | 2002-12-03 | 2012-02-23 | 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 | 치료제와 연결된 콜레스테롤을 포함하는 접합체 |
| JP2006512417A (ja) | 2002-12-24 | 2006-04-13 | ニューロケム （インターナショナル） リミテッド | β−アミロイド関連疾患の治療のための治療用製剤 |
| US20050089473A1 (en) | 2003-09-10 | 2005-04-28 | Cedars-Sinai Medical Center | Potassium channel mediated delivery of agents through the blood-brain barrier |
| CN101325972B (zh) * | 2005-12-12 | 2020-06-16 | Ac免疫有限公司 | 具有治疗性质的Aβ1-42特异性单克隆抗体 |
| US8428434B2 (en) * | 2006-10-23 | 2013-04-23 | Pioneer Corporation | Video reproducing apparatus, video display system and record medium |
| WO2008140639A2 (en) * | 2007-02-08 | 2008-11-20 | Oligomerix, Inc. | Biomarkers and assays for alzheimer's disease |
| CA2692039C (en) | 2007-06-13 | 2019-07-02 | Research Development Foundation | Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating crf receptor signaling |
| US9403902B2 (en) * | 2007-10-05 | 2016-08-02 | Ac Immune S.A. | Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody |
| KR20100115340A (ko) * | 2007-10-19 | 2010-10-27 | 이무나스 파마 가부시키가이샤 | Ａβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용 |
| CN106390107B (zh) * | 2009-06-10 | 2019-12-31 | 纽约大学 | 病理tau蛋白的免疫靶向 |
| KR20130127547A (ko) | 2009-07-30 | 2013-11-22 | 화이자 백신스 엘엘씨 | 항원성 타우 펩타이드 및 이의 용도 |
| CN102070718A (zh) | 2010-03-23 | 2011-05-25 | 中国疾病预防控制中心病毒病预防控制所 | 人tau蛋白外显子2、外显子3、外显子10多克隆抗体 |
| MY164376A (en) | 2010-10-07 | 2017-12-15 | Univ Leuven Kath | Phosphospecific antibodies recognizing tau |
| AR092779A1 (es) | 2011-10-07 | 2015-05-06 | Ac Immune Sa | Composicon farmaceutica que comprende anticuerpos que se unen a conformeros de proteinas tau |
| CA2869438C (en) * | 2012-04-05 | 2021-08-17 | Ac Immune S.A. | Humanized tau antibody |
| WO2013166302A1 (en) | 2012-05-02 | 2013-11-07 | Ibis Biosciences, Inc. | Nucleic acid sequencing systems and methods |
-
2012
- 2012-10-05 AR ARP120103738A patent/AR092779A1/es unknown
- 2012-10-05 MX MX2014004026A patent/MX354662B/es active IP Right Grant
- 2012-10-05 ES ES12769656.5T patent/ES2600915T3/es active Active
- 2012-10-05 EP EP16180969.4A patent/EP3135689B1/en active Active
- 2012-10-05 US US14/348,918 patent/US9540434B2/en active Active
- 2012-10-05 CA CA2850686A patent/CA2850686C/en active Active
- 2012-10-05 KR KR1020147012061A patent/KR101981351B1/ko active IP Right Grant
- 2012-10-05 BR BR122021017560-8A patent/BR122021017560B1/pt active IP Right Grant
- 2012-10-05 EP EP12769656.5A patent/EP2764022B9/en active Active
- 2012-10-05 RU RU2014118456A patent/RU2639537C2/ru active
- 2012-10-05 CN CN201711419092.7A patent/CN108034005B/zh active Active
- 2012-10-05 CN CN201280060349.3A patent/CN104080806B/zh active Active
- 2012-10-05 BR BR112014008202-2A patent/BR112014008202B1/pt active IP Right Grant
- 2012-10-05 WO PCT/EP2012/069783 patent/WO2013050567A1/en active Application Filing
- 2012-10-05 JP JP2014533928A patent/JP6358953B2/ja active Active
-
2015
- 2015-01-28 HK HK15100957.4A patent/HK1200469A1/zh unknown
-
2016
- 2016-10-28 US US15/337,964 patent/US10066010B2/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090162336A1 (en) * | 1991-12-06 | 2009-06-25 | Max-Planck-Gesellschaft Zur Forderungder Wissenschaften, E.V. | Novel Tools for the Diagnosis and Treatment of Alzheimer's Disease |
| WO1998022120A1 (en) * | 1996-11-19 | 1998-05-28 | The Wistar Institute Of Anatomy & Biology | Diagnostic and therapeutic reagents for alzheimer's disease |
| RU2299889C2 (ru) * | 2001-02-02 | 2007-05-27 | Аксон Нойрошинс Форшунгс-Унд Энтвиклунгс Гмбх | Конформационно аномальные формы белков тау и специфические антитела к ним |
| US20080050383A1 (en) * | 2006-03-29 | 2008-02-28 | New York University | Immunotherapy for clearing pathological tau conformers |
| WO2010106127A2 (en) * | 2009-03-18 | 2010-09-23 | Ac Immune S.A. | Method for therapeutic use |
| WO2010115843A2 (en) * | 2009-04-03 | 2010-10-14 | Ac Immune S.A. | Pharmaceutical composition |
Non-Patent Citations (3)
| Title |
|---|
| BUÉE-SCHERER V. et al. "AD2, a phosphorylation-dependent monoclonal antibody directed against tau proteins found in Alzheimer's disease." Molecular brain research, 1996, 39(1): 79-88. * |
| OTVOS L. et al. "Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404." Journal of neuroscience research, 1994, 39(6): 669-673. * |
| OTVOS L. et al. "Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404." Journal of neuroscience research, 1994, 39(6): 669-673. BUÉE-SCHERER V. et al. "AD2, a phosphorylation-dependent monoclonal antibody directed against tau proteins found in Alzheimer's disease." Molecular brain research, 1996, 39(1): 79-88. * |
Also Published As
| Publication number | Publication date |
|---|---|
| US9540434B2 (en) | 2017-01-10 |
| KR101981351B1 (ko) | 2019-09-02 |
| MX2014004026A (es) | 2014-08-27 |
| CN108034005A (zh) | 2018-05-15 |
| BR112014008202A2 (zh) | 2017-08-15 |
| RU2014118456A (ru) | 2015-11-20 |
| BR112014008202B1 (pt) | 2022-01-04 |
| US10066010B2 (en) | 2018-09-04 |
| CN104080806B (zh) | 2018-01-19 |
| EP2764022B1 (en) | 2016-08-17 |
| CA2850686C (en) | 2020-09-08 |
| WO2013050567A1 (en) | 2013-04-11 |
| EP2764022A1 (en) | 2014-08-13 |
| EP3135689A1 (en) | 2017-03-01 |
| ES2600915T3 (es) | 2017-02-13 |
| US20170137502A1 (en) | 2017-05-18 |
| CA2850686A1 (en) | 2013-04-11 |
| AR092779A1 (es) | 2015-05-06 |
| EP2764022B9 (en) | 2017-02-22 |
| MX354662B (es) | 2018-03-14 |
| EP3135689B1 (en) | 2018-12-19 |
| CN108034005B (zh) | 2021-06-25 |
| BR122021017560B1 (pt) | 2023-03-07 |
| US20140294731A1 (en) | 2014-10-02 |
| CN104080806A (zh) | 2014-10-01 |
| HK1200469A1 (zh) | 2015-08-07 |
| KR20140070658A (ko) | 2014-06-10 |
| JP6358953B2 (ja) | 2018-07-18 |
| JP2014531216A (ja) | 2014-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2639537C2 (ru) | Фосфоспецифичные антитела, распознающие тау | |
| US10100104B2 (en) | Methods of diagnosing tau-protein-associated disease | |
| CA2869438C (en) | Humanized tau antibody | |
| AU2013205313B2 (en) | Phosphospecific antibodies recognising tau | |
| TW201321409A (zh) | 醫藥組合物 | |
| AU2016202289A1 (en) | Phosphospecific antibodies recognising tau |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC9A | Changing information about inventors |